The colorectal cancer market in North America is expected to grow from US$ 8,559.27 million in 2022 to US$ 11,198.11 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.
Colorectal cancer is one of the most commonly found lethal cancers in individuals with the combined influence of genetic and environmental factors. A significant population in North America is diagnosed with colorectal cancer. According to the Centers for Disease Control and Prevention (CDC) and the American Cancer Society, an estimated 1.93 million adults in the US were diagnosed with colon and rectum cancer, and 53,200 deaths were caused by colorectal cancer in 2020. These statistics showcase increased demand for advanced cancer diagnostics and therapeutics in the region. Thus, the rising prevalence of colorectal cancer and the rising number of patients diagnosed with the disease are driving the growth of the North America colorectal cancer market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America colorectal cancer market at a substantial CAGR during the forecast period.
Colorectal cancer is one of the most commonly found lethal cancers in individuals with the combined influence of genetic and environmental factors. A significant population in North America is diagnosed with colorectal cancer. According to the Centers for Disease Control and Prevention (CDC) and the American Cancer Society, an estimated 1.93 million adults in the US were diagnosed with colon and rectum cancer, and 53,200 deaths were caused by colorectal cancer in 2020. These statistics showcase increased demand for advanced cancer diagnostics and therapeutics in the region. Thus, the rising prevalence of colorectal cancer and the rising number of patients diagnosed with the disease are driving the growth of the North America colorectal cancer market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America colorectal cancer market at a substantial CAGR during the forecast period.
North America Colorectal Cancer Market Segmentation
The North America colorectal cancer market is segmented into modality, end user, and country.- Based on modality, the North America colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. In 2022, the diagnosis type segment held the largest market share and is expected to register the highest CAGR during the forecast period.
- Based on end user, the North America colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. In 2022, the hospitals segment held a larger market share.
- Based on country, the North America colorectal cancer market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. North America Colorectal Cancer- Market Landscape
5. North America Colorectal Cancer Market - Key Market Dynamics
6. North America Colorectal Cancer Market- North America Analysis
7. North America Colorectal Cancer Market Analysis - By Modality
8. North America Colorectal Cancer Market Revenue and Forecast To 2028 - By End User
9. North America Colorectal Cancer Market Revenue and Forecast to 2028 - Country Analysis
10. Colorectal Cancer Market - Industry Landscape
11. Company Profiles
12. Appendix
Companies Mentioned
- Abbott
- Amgen Inc.
- Bruker Corporation
- Clinical Genomics Technologies Pty Ltd.
- Epigenomics AG
- F. Hoffmann-La Roche AG
- Quest Diagnostics
- VolitionRx Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 157 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 8559.27 Million |
| Forecasted Market Value ( USD | $ 11198.11 Million |
| Compound Annual Growth Rate | 3.4% |
| Regions Covered | North America |
| No. of Companies Mentioned | 8 |
